CYCS Antibody

What is the CYCS protein and why is it important in research?

CYCS (cytochrome c, somatic) is a 105-amino acid residue protein encoded by the CYCS gene in humans. This highly conserved mobile electron transport protein is essential for energy conversion in all aerobic organisms. In mammalian cells, it's normally localized to the mitochondrial inter-membrane space and features phosphorylated post-translational modifications. Beyond its role in the electron transport chain, CYCS has gained significant research attention for its involvement in the apoptotic pathway. During apoptosis, CYCS translocates from mitochondria to the cytosol, where it activates caspase cascades leading to programmed cell death. Other synonyms for Cytochrome C include CYC, HCS, and THC4 . This dual functionality makes CYCS a critical target for research in fields ranging from cancer biology to neurodegenerative diseases.

What is the difference between apocytochrome and holocytochrome C, and why does it matter for antibody selection?

When selecting CYCS antibodies, researchers must consider whether they need detection of all CYCS forms. Apocytochrome refers to cytochrome c in the cytosol without heme attached, while holocytochrome refers to cytochrome c in the mitochondria with heme attached . This distinction is crucial because:

• Subcellular localization studies may require antibodies that detect both forms

• Functional studies might need to distinguish between the forms

• Apoptosis research benefits from antibodies recognizing total cytochrome C

Some antibodies, like the monoclonal antibody described in source , recognize total cytochrome C, including both apocytochrome and holocytochrome forms. Researchers should verify antibody specificity for their particular experimental needs, especially when studying CYCS translocation during apoptosis.

How should I evaluate epitope specificity when selecting a CYCS antibody?

Evaluating epitope specificity is essential for experimental success with CYCS antibodies. Consider these methodological approaches:

• Identify the target epitope region - Some antibodies target specific regions (e.g., amino acids 93-104 of pigeon Cytochrome C or AA 2-105 )

• Consider cross-reactivity with other species - CYCS is highly conserved, so check species reactivity data

• Evaluate recognition of post-translational modifications - Some modifications may affect antibody binding

• Test multiple antibodies targeting different epitopes - This validates findings across different recognition sites

• Consider application compatibility - Some epitopes may be accessible only in certain experimental contexts

For critical experiments, perform validation using recombinant CYCS protein or cell lines with known CYCS expression patterns. The epitope location can significantly impact experimental outcomes, particularly in studies examining CYCS conformational changes during apoptosis.

What are the most effective applications for CYCS antibodies in apoptosis research?

CYCS antibodies are invaluable tools for studying apoptotic processes. Based on the search results, the most effective methodological approaches include:

• Western blotting for translocation studies:

  • Perform subcellular fractionation to separate mitochondrial and cytosolic compartments

  • Blot fractions to quantify CYCS redistribution during apoptosis

  • Include mitochondrial markers (e.g., COX15) to verify fractionation quality

• Immunohistochemistry for tissue analysis:

  • Use in both paraffin-embedded (IHC-p) and frozen sections (IHC-fr)

  • Evaluate mitochondrial staining pattern in normal cells versus diffuse cytoplasmic pattern in apoptotic cells

  • Counterstain to identify cellular context of CYCS expression

• Immunocytochemistry for subcellular localization:

  • Co-stain with mitochondrial markers to track CYCS movement

  • Use confocal microscopy for high-resolution imaging

  • Implement time-course experiments to capture dynamic translocation

• Flow cytometry for quantitative analysis:

  • Measure intracellular CYCS in intact and permeabilized cells

  • Combine with annexin V staining to correlate with apoptotic stages

  • Analyze population distributions with algorithms like SPADE or viSNE

These applications can be combined to provide comprehensive insights into CYCS behavior during the apoptotic cascade.

How can I optimize Western blot protocols specifically for CYCS detection?

Optimizing Western blot protocols for the relatively small (~12-15 kDa) CYCS protein requires specific methodological considerations:

• Sample preparation:

  • Use gentle lysis buffers with protease inhibitors to preserve protein integrity

  • For translocation studies, employ careful subcellular fractionation techniques

  • Include phosphatase inhibitors if studying phosphorylated forms

• Gel electrophoresis:

  • Use higher percentage (15-20%) polyacrylamide gels for better resolution of small proteins

  • Load appropriate molecular weight markers covering the 10-20 kDa range

  • Consider gradient gels for simultaneous analysis of CYCS and binding partners

• Transfer conditions:

  • Optimize transfer time (shorter for small proteins)

  • Use PVDF membranes with smaller pore sizes (0.2 μm) to prevent protein loss

  • Consider semi-dry transfer systems which often work well for small proteins

• Antibody selection and dilution:

  • Test multiple antibodies targeting different epitopes

  • Optimize antibody dilution (typically 1:500 to 1:2000)

  • Extend primary antibody incubation time (overnight at 4°C)

• Detection and visualization:

  • Use high-sensitivity ECL reagents for clear signal detection

  • Consider signal enhancement systems for detecting low abundance cytosolic CYCS

  • Implement digital imaging for accurate quantification

Following these methodological adjustments should yield clear, reproducible detection of CYCS in various experimental contexts.

What controls are essential when using CYCS antibodies for immunohistochemistry?

Robust controls are critical for reliable CYCS immunohistochemistry results. Implement these methodological controls:

• Positive controls:

  • Tissues with known CYCS expression (CYCS is widely expressed across tissues)

  • Tissues with induced apoptosis (e.g., cancer tissues treated with chemotherapy)

  • Cell pellets from cell lines with confirmed CYCS expression

• Negative controls:

  • Primary antibody omission (to detect non-specific binding of secondary antibody)

  • Isotype controls (matching host species and antibody isotype)

  • Blocking peptide competition (pre-incubation with immunizing peptide)

• Subcellular localization controls:

  • Co-staining with mitochondrial markers (for normal localization)

  • Co-staining with apoptotic markers (for translocation verification)

  • Nuclear counterstaining to provide cellular context

• Technical controls:

  • Antigen retrieval optimization (critical for formalin-fixed tissues)

  • Titration of antibody concentration

  • Comparison of different detection systems

• Biological context controls:

  • Normal vs. apoptotic tissues

  • Treatment with apoptosis inducers vs. inhibitors

  • Comparison across multiple tissue types

Implementing these controls ensures valid interpretation of CYCS staining patterns and minimizes false-positive or false-negative results.

How can high-dimensional data analysis be applied to CYCS studies?

High-dimensional data analysis techniques offer powerful approaches for CYCS research, particularly when studying heterogeneous cell populations or complex tissue samples. Based on search result , these methodological approaches include:

• SPADE (Spanning-tree Progression Analysis of Density-normalized Events):

  • Hierarchically clusters cells by phenotypic similarity

  • Settings: target number of nodes (~200), percent downsampling (10%)

  • Allows visualization of CYCS expression across diverse cell populations

  • Enables quantification of cellular abundance in specific nodes

• viSNE:

  • Displays cells as a continuum of phenotypes

  • Useful for visualizing subtle changes in CYCS expression patterns

  • Preserves local similarities between cells in high-dimensional space

• Citrus:

  • Identifies statistically significant differences between experimental groups

  • Settings: PAMR association model, cluster characterization (abundance or expression), false discovery rate (1%)

  • Tests for predictive models with statistical power to discriminate between groups

  • Particularly valuable for comparing CYCS expression between normal and disease states

• PhenoGraph and X-shift:

  • Stratify cells into subpopulations based on marker expression

  • Quantify changes in population structure under different conditions

  • Useful for tracking shifts in CYCS-expressing populations during experimental interventions

Implementation requires sufficient sample size (n ≥ 3), with careful attention to algorithm-specific parameters and cross-validation approaches .

What methods can be used to study CYCS variants associated with disease?

Research into CYCS variants associated with diseases like thrombocytopenia-4 (THC4) requires comprehensive methodological approaches. Based on search result , effective strategies include:

• Genetic analysis:

  • Sequencing to identify novel variants (e.g., CYCS variant c.59C>T [p.(Thr20Ile)])

  • Segregation analysis across multiple generations

  • Evolutionary conservation assessment

• CRISPR/Cas9-mediated gene editing:

  • Introduction of specific CYCS variants into cell lines (e.g., MEG-01 megakaryoblast cells)

  • Creation of isogenic cell models for comparative studies

  • Precise manipulation of single nucleotide changes

• Functional characterization:

  • Cell adhesion, shape, size, and ploidy analysis

  • Viability assessment under various conditions

  • Mitochondrial respiration measurements

  • CYCS protein expression quantification

  • Cell surface antigen expression analysis (e.g., CD9)

• Caspase activity analysis:

  • Comparison with wild-type cells

  • Assessment of baseline and stimulated caspase activation

  • Correlation with cellular phenotypes

• Phenotypic analysis:

  • For thrombocytopenia, quantification of platelet counts

  • Morphological assessment of platelets

  • Inheritance pattern documentation

These approaches have revealed that CYCS variants can have diverse effects, with some (like the novel variant described) decreasing caspase activity, contrary to other known variants. This dysregulation of caspase activity might contribute to disease mechanisms like thrombocytopenia .

How can I differentiate between normal and pathological CYCS functions in experimental models?

Differentiating normal from pathological CYCS functions requires multi-parameter analysis approaches:

• Localization studies:

  • Normal: Primarily mitochondrial localization

  • Pathological: Inappropriate cytosolic accumulation or abnormal mitochondrial distribution

  • Methodology: Subcellular fractionation followed by immunoblotting; immunofluorescence with mitochondrial co-staining

• Expression level analysis:

  • Quantitative PCR for mRNA expression

  • Western blot with calibrated standards for protein quantification

  • Flow cytometry for single-cell expression distribution

  • Compare with reference ranges for the specific cell type

• Functional assays:

  • Electron transport function: Cytochrome c oxidase activity assays

  • Apoptotic function: Caspase activation, PARP cleavage, DNA fragmentation

  • Disease-specific functions: For thrombocytopenia, assess impacts on megakaryocyte development

• Variant characterization:

  • For variants like the thrombocytopenia-4-causing CYCS variant, analyze:

    • Effects on mitochondrial respiration (may be increased)

    • Impact on caspase activation (may be decreased)

    • Changes in cell surface markers (e.g., CD9 expression)

• Cell-specific functional tests:

  • For thrombocytopenia: Platelet aggregation studies

  • For neurodegeneration: Neurite outgrowth or synaptic function

  • For cancer: Apoptotic resistance assessments

These methodological approaches provide complementary information about CYCS function in different contexts, allowing for comprehensive assessment of normal versus pathological roles.

What are common challenges in detecting cytosolic versus mitochondrial CYCS, and how can they be overcome?

Distinguishing between cytosolic and mitochondrial CYCS poses several methodological challenges:

• Challenge: Cross-contamination during subcellular fractionation

  • Solution: Use gentle lysis conditions and optimize centrifugation protocols

  • Validation: Blot for compartment-specific markers (e.g., COX IV for mitochondria, GAPDH for cytosol)

  • Control: Include fractionation controls in every experiment

• Challenge: Low signal from cytosolic CYCS in non-apoptotic cells

  • Solution: Use high-sensitivity detection methods (enhanced chemiluminescence)

  • Methodology: Concentrate cytosolic fractions before analysis

  • Alternative: Consider proximity ligation assays for in situ detection

• Challenge: Antibodies with preferential binding to either apo- or holo-cytochrome c

  • Solution: Select antibodies that recognize both forms (as described in sources and )

  • Validation: Test antibody recognition with recombinant CYCS with and without heme

  • Control: Use multiple antibodies targeting different epitopes

• Challenge: Difficulty visualizing translocation in tissue samples

  • Solution: Implement multi-label immunofluorescence with mitochondrial markers

  • Methodology: Use super-resolution microscopy for improved spatial resolution

  • Alternative: Consider tissue clearing techniques for 3D visualization

• Challenge: Quantifying the degree of CYCS translocation

  • Solution: Implement digital image analysis with mitochondrial co-localization

  • Methodology: Calculate Pearson's correlation coefficient between CYCS and mitochondrial signals

  • Validation: Correlate with functional apoptotic readouts (caspase activation)

These methodological approaches help overcome the technical challenges associated with accurately differentiating and quantifying CYCS in different subcellular compartments.

How can I assess the quality and accuracy of antibody microarray experiments involving CYCS?

Quality control for antibody microarray experiments involving CYCS requires rigorous methodology. Based on search result , an experimental strategy involves:

• Dual-labeling approach:

  • Label two aliquots of the protein sample with different fluorophores (e.g., Cy3 and Cy5)

  • Incubate microarray slide #1 with mixture containing X amount of Cy3-labeled proteins and Y amount of Cy5-labeled proteins

  • Incubate microarray slide #2 with mixture containing X amount of Cy5-labeled proteins and Y amount of Cy3-labeled proteins

  • Calculate ratio analysis for target proteins at specific spots

• Quality control metrics:

  • Assess signal-to-noise ratios

  • Evaluate spot morphology and uniformity

  • Check for spatial biases across the array

  • Implement dye-swap experiments to control for dye-specific biases

• Data normalization approaches:

  • Global normalization across arrays

  • Use of housekeeping proteins as internal controls

  • Implement spike-in controls at known concentrations

• Validation experiments:

  • Confirm key findings with orthogonal methods (e.g., ELISA, Western blot)

  • Test biological replicates to assess reproducibility

  • Implement positive and negative controls for each experiment

This experimental design eliminates the need for exogenous reference markers and doesn't require determining absolute concentrations of individual proteins, making it practical for routine laboratory use .

What factors can affect CYCS antibody specificity and how can they be mitigated?

Multiple factors can affect CYCS antibody specificity, each requiring specific mitigation strategies:

• Epitope accessibility issues:

  • Problem: Conformational changes during apoptosis may mask epitopes

  • Mitigation: Use antibodies targeting different epitopes

  • Validation: Compare results across multiple antibodies

• Cross-reactivity with related proteins:

  • Problem: Similar cytochromes may share sequence homology

  • Mitigation: Validate antibody specificity with knockout/knockdown controls

  • Testing: Perform peptide competition assays

• Post-translational modifications:

  • Problem: Phosphorylation or other modifications may affect antibody binding

  • Mitigation: Use antibodies verified to be modification-insensitive or modification-specific

  • Controls: Test with recombinant proteins with defined modification states

• Sample preparation artifacts:

  • Problem: Fixation can alter epitope accessibility and protein localization

  • Mitigation: Optimize fixation protocols for CYCS detection

  • Comparison: Test multiple fixation methods with the same antibody

• Antibody format and quality:

  • Problem: Lot-to-lot variability in polyclonal antibodies

  • Mitigation: Use monoclonal antibodies for critical applications

  • Testing: Validate each new antibody lot before use

• Non-specific binding:

  • Problem: High background in certain tissues or cell types

  • Mitigation: Optimize blocking conditions and washing steps

  • Controls: Include isotype controls and secondary-only controls

Implementation of these methodological approaches ensures reliable and specific detection of CYCS across different experimental contexts.

How are CYCS antibodies being used in thrombocytopenia research?

CYCS antibodies play a crucial role in investigating the mechanisms underlying thrombocytopenia-4 (THC4), a condition linked to CYCS gene variants. Based on search result , current methodological approaches include:

• Gene variant characterization:

  • Identification of novel variants like CYCS c.59C>T [p.(Thr20Ile)]

  • Tracking inheritance patterns across generations

  • Correlating genotypes with clinical phenotypes

• Megakaryocyte development studies:

  • Using megakaryoblast cell lines (e.g., MEG-01) with CRISPR/Cas9-edited CYCS variants

  • Analyzing adhesion, shape, size, ploidy, and viability

  • Tracking mitochondrial respiration changes

• CYCS protein expression analysis:

  • Quantifying expression levels in patient samples

  • Comparing wild-type vs. variant CYCS expression in cell models

  • Assessing subcellular localization patterns

• Downstream pathway investigation:

  • Measuring caspase activity changes (decreased in the novel variant)

  • Analyzing cell surface antigen expression (e.g., increased CD9)

  • Connecting these molecular changes to thrombocytopenia mechanisms

• Translational applications:

  • Using antibodies to track CYCS expression in patient platelets

  • Developing diagnostic tools based on CYCS localization or expression

  • Evaluating therapeutic responses at the molecular level

These approaches have revealed surprising findings, such as the decreased caspase activity associated with the novel CYCS variant, contrasting with previously known effects of other variants. This suggests that dysregulation of caspase activity might contribute to thrombocytopenia through mechanisms involving thrombopoiesis .

What are the latest developments in conjugated CYCS antibodies for advanced imaging?

Conjugated CYCS antibodies have expanded significantly, offering researchers powerful tools for advanced imaging applications. According to sources and , current options include:

These conjugates enable:

• Multi-parameter imaging of CYCS alongside other apoptotic markers

• Live-cell tracking of CYCS translocation during apoptosis

• Super-resolution visualization of CYCS within mitochondrial structures

• Quantitative analysis of CYCS distribution in complex tissues

Researchers should note that conjugates of blue fluorescent dyes like CF®405S are not recommended for detecting low abundance targets due to lower fluorescence and potential higher non-specific background .

How can antibody developability assessment be applied to improve CYCS antibody research?

Applying antibody developability assessment principles to CYCS antibody research can significantly enhance experimental outcomes. Based on search result , methodological approaches include:

• Physicochemical property evaluation:

  • Assess self-interaction and aggregation tendencies

  • Measure thermal and colloidal stability

  • Optimize properties through sequence engineering

• High-throughput developability workflow:

  • Implement screening for hundreds to thousands of antibody candidates

  • Assess critical developability parameters alongside binding affinity

  • Use minimal amounts of purified material (<100 μg)

• Quality attributes to evaluate:

  • Target specificity across CYCS epitopes

  • Cross-reactivity with related cytochromes

  • Stability under experimental conditions

  • Performance across multiple applications (Western, IHC, flow cytometry)

• Integration with biological characterization:

  • Combine developability assessment with functional testing

  • Correlate physical properties with experimental performance

  • Select candidates based on both technical and biological criteria

This systematic approach allows researchers to select optimal CYCS antibodies that combine excellent technical properties (stability, specificity) with strong biological performance, facilitating more reliable and reproducible research outcomes .

What emerging technologies are likely to impact CYCS antibody applications in the next five years?

Several emerging technologies are poised to transform CYCS antibody applications:

• Single-cell proteomics:

  • Combining CYCS antibodies with mass cytometry (CyTOF) for deep phenotyping

  • Integration with single-cell transcriptomics for multi-omic analysis

  • Enhanced algorithms for high-dimensional data analysis

• Advanced imaging technologies:

  • Expansion microscopy for subcellular visualization of CYCS translocation

  • Light-sheet microscopy for 3D tissue imaging with minimal photodamage

  • Correlative light and electron microscopy for ultrastructural context

• Engineered antibody formats:

  • Single-domain antibodies for improved tissue penetration

  • Bispecific antibodies targeting CYCS and binding partners

  • Intrabodies for live-cell tracking of CYCS dynamics

• Computational approaches:

  • AI-assisted image analysis for quantifying CYCS translocation

  • Machine learning algorithms for predicting antibody-epitope interactions

  • In silico modeling of CYCS variants and their functional impacts

• Therapeutic applications:

  • Targeting dysregulated CYCS in thrombocytopenia and other disorders

  • Developing antibodies that modulate CYCS functions

  • CYCS-based biomarkers for disease stratification

These technological advances will enable more precise characterization of CYCS functions in normal physiology and disease, potentially leading to novel diagnostic and therapeutic strategies.

What are critical considerations for researchers transitioning from basic CYCS studies to disease-specific applications?

Researchers transitioning to disease-specific CYCS applications should consider these methodological principles:

• Disease-relevant model selection:

  • Choose appropriate cell types (e.g., MEG-01 cells for thrombocytopenia)

  • Consider patient-derived samples or primary cells

  • Develop disease-specific functional readouts

• Variant characterization strategy:

  • Implement comprehensive functional assessment of variants

  • Compare multiple variants to identify common mechanisms

  • Correlate molecular findings with clinical phenotypes

• Mechanistic depth:

  • Move beyond correlative studies to establish causality

  • Connect CYCS abnormalities to specific disease manifestations

  • Identify potential points for therapeutic intervention

• Translational considerations:

  • Develop standardized protocols applicable to clinical samples

  • Establish reproducible biomarkers for disease monitoring

  • Consider specificity and sensitivity in diagnostic applications

• Collaborative approach:

  • Partner with clinicians for access to patient samples

  • Engage with computational biologists for data analysis

  • Work with structural biologists to understand variant impacts